Therefore, further isolation of bioactive compounds and pre-clinical testing should be considered for CA and PS to identify the compounds responsible for the stimulation of CD82, and correlating anti-invasive activity, as a novel therapeutic mechanism against breast cancer. Here, CD82 is linked to breast cancer.